Mefenorex

Mefenorex
Clinical data
Trade names	Rondimen, Pondinil, Anexate
ATC code	A08AA09 (WHO) ;
Legal status
Legal status	BR: Class B2 (Anorectic drugs); CA: Schedule I; DE: Anlage II (Authorized trade only, not prescriptible);
Identifiers
	IUPAC name 3-chloro-N-(1-methyl-2-phenylethyl)propan-1-amine;
CAS Number	17243-57-1 ;
PubChem CID	21777;
ChemSpider	20467 ;
UNII	K98M4N387W;
KEGG	D07891 ;
CompTox Dashboard (EPA)	DTXSID6057665 ;
ECHA InfoCard	100.037.511
Chemical and physical data
Formula	C12H18ClN
Molar mass	211.73 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClCCCNC(Cc1ccccc1)C;
	InChI InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3 ; Key:XXVROGAVTTXONC-UHFFFAOYSA-N ;
	(verify)

Mefenorex (Rondimen, Pondinil, Anexate) is a stimulant drug which was used as an appetite suppressant. It is an amphetamine derivative which was developed in the 1970s and used for the treatment of obesity.^[2]^[3] Mefenorex produces amphetamine as a metabolite,^[4] and has been withdrawn in many countries despite having only mild stimulant effects and relatively little abuse potential.^[5]

^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
^ Vincendeau MJ (1970). "[A new regulator of appetite: mefenorex]". Bordeaux Medical (in French). 3 (7): 1951–3. PMID 5455004.
^ Beyer G, Huth K, Müller GM, Niemöller H, Raisp I, Vorberg G (February 1980). "[The treatment of obesity with the appetite curbing agent Mefenorex]". Die Medizinische Welt (in German). 31 (8): 306–9. PMID 7374423.
^ Rendić S, Slavica M, Medić-Sarić M (1994). "Urinary excretion and metabolism of orally administered mefenorex". European Journal of Drug Metabolism and Pharmacokinetics. 19 (2): 107–17. doi:10.1007/BF03188831. PMID 8001591. S2CID 7170057.
^ Engel J, Kristen G, Schaefer A, von Schlichtegroll A (June 1986). "Mefenorex (Rondimen)". Drug and Alcohol Dependence. 17 (2–3): 229–34. doi:10.1016/0376-8716(86)90010-4. PMID 3743406.

[1] Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

[pmid5455004-2] Vincendeau MJ (1970). "[A new regulator of appetite: mefenorex]". Bordeaux Medical (in French). 3 (7): 1951–3. PMID 5455004.

[pmid7374423-3] Beyer G, Huth K, Müller GM, Niemöller H, Raisp I, Vorberg G (February 1980). "[The treatment of obesity with the appetite curbing agent Mefenorex]". Die Medizinische Welt (in German). 31 (8): 306–9. PMID 7374423.

[pmid8001591-4] Rendić S, Slavica M, Medić-Sarić M (1994). "Urinary excretion and metabolism of orally administered mefenorex". European Journal of Drug Metabolism and Pharmacokinetics. 19 (2): 107–17. doi:10.1007/BF03188831. PMID 8001591. S2CID 7170057.

[pmid3743406-5] Engel J, Kristen G, Schaefer A, von Schlichtegroll A (June 1986). "Mefenorex (Rondimen)". Drug and Alcohol Dependence. 17 (2–3): 229–34. doi:10.1016/0376-8716(86)90010-4. PMID 3743406.

[1]

[2]

[3]

[4]

[5]